About the Company
Corbus Pharmaceuticals (CRBP) is a clinical-stage pharmaceutical business dedicated to the discovery and commercialization of new medicines for the treatment of uncommon, chronic, and severe inflammatory and fibrotic illnesses with significant unmet medical needs. Anabasum is a new synthetic oral endocannabinoid-mimetic medication that is designed to cure chronic inflammation and stop fibrotic processes without inducing immunosuppression. Anabasum is being developed to treat four potentially fatal diseases: systemic sclerosis, cystic fibrosis, diffuse cutaneous, skin-predominant dermatomyositis, and systemic lupus erythematosus ("SLE"). The FDA of the US has given anabasum Orphan Designation and Fast Track Status for cystic fibrosis and systemic sclerosis.;
Organisation | Corbus Pharmaceuticals Holdings Inc |